Surgical Versus Non-Surgical Treatment of Thoracolumbar Burst Fracture (A34RCT)

Outcome of Surgical Versus Primary Non-Surgical Treatment of Traumatic Thoracolumbar Spine Burst Fracture in Patients Without Neurological Symptoms: A Randomized Controlled Clinical Trial

Treatment for acute traumatic thoracolumbar burst fractures differs significantly across the world in patients without neurological impairments and without damage to the posterior column of the spine. This randomized controlled, non-inferiority clinical trial's goal is to evaluate the effectiveness of surgery versus initial non-surgical treatment for patients with traumatic thoracolumbar spine burst fractures who don't have any neurological symptoms.

The study's precise objectives are to:

  1. evaluate the clinical outcome (Oswestry Disability Index)
  2. evaluate the radiography result (restoration and maintenance of spinal alignment)
  3. determine the prevalence of complications

at least 24 months of follow-up of neurologically unaffected patients with acute traumatic burst fractures. Both groups will get the same therapy using standardized methods: The surgical group's entire patient population will get combined anterior-posterior (360°) spinal fusion therapy. Three-point hyperextension orthoses will be used to treat all patients in the non-surgical group for six weeks following the injury.

Study Overview

Detailed Description

The research is a single-center, nationwide, randomized controlled trial. Over a two-year period, 52 patients with a thoracolumbar burst fracture will enroll in the study. They will be assigned randomly (1:1) to either non-surgical treatment with a brace or surgery with anterior-posterior fixation. A prospective data collection will be asked of subjects who decline randomization (observational arm). The subjects will be evaluated clinically, radiologically, and based on patient-reported outcomes over the course of two years. Both patient files and questionnaires will be used to collect data.

Study Type

Interventional

Enrollment (Estimated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18 - 70 years at inclusion
  • Acute traumatic burst fracture of the thoracolumbar spine (10th thoracic to 3rd lumbar vertebral body)
  • Informed consent for study participation

Exclusion Criteria:

  • Injury of the posterior tension band/posterior column of the thoracolumbar spine
  • Any neurological deficit (American Spinal Injury Association Impairment Scale [AISA] Grade A-D)
  • Pathological vertebral body fractures (diagnosed by MRI and CT scan), which, in the opinion of the research/investigative team, would compromise (or interfere with) patients' ability to participate in the study
  • Concomitant spinal fractures at any other level of the spine outside the T10-L3 level, which, in the opinion of the research/investigative team, would compromise (or interfere with) patients' ability to participate in the study
  • Multiple trauma or Injury Severity Score (ISS) > 16 or additional injuries according to the investigator may, which, in the opinion of the research/investigative team, would compromise (or interfere with) patients' ability to participate in the study (impairment of early ambulation)
  • Any known previous spinal surgery in the thoracolumbar spine, which, in the opinion of the research/investigative team, would compromise (or interfere with) patients' ability to participate in the study
  • Any severe, progressive, or uncontrolled medical or psychiatric condition, or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study
  • Known history of substance abuse (i.e., recreational drugs, alcohol) that would preclude reliable assessment in the opinion of the investigator
  • Pregnancy or women planning to conceive within the study period. All women included in this study must have a negative blood pregnancy test (human chorionic gonadotrophin (hCG) blood level at visit 1. If pregnancy occurs during the study period, the patients drop out of the study
  • Inability to follow the procedures of the study, e.g., due to inability to understand German, French or English, which, according to the investigator, may jeopardize the patient in case of participation in the study or prevents the patient from participating in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Surgical treatment
The surgeon will perform a minimally invasive (percutaneous) posterior stabilization of the injured spinal segments. Transpedicular screws will be inserted into the vertebral body superior and inferior to the fractured vertebra under fluoroscopic control. In a second stage procedure a lumbo- or thoracotomy (depending on the fracture level below or above the diaphragm) is performed to remove the fractured part of the vertebral body (hemicorporectomy) including the intervertebral disc segments. The resulting void is replaced by an (expandable) spacer/cage.
Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
Other Names:
  • 360°-Stabilization
No Intervention: Non-surgical treatment
The patients will receive an external bracing (3-point hyperextension brace) for six weeks, which must be always worn except when lying flat in bed. The brace is adjusted by an experienced orthopedist. A physiotherapist will instruct the patient to accomplish daily activities with the restriction he or she will have by wearing the brace.
Other: Observational arm
Patients who do not agree to randomization will be given the option to participate in the observational arm of the study. Their treatment will be surgical fixation with an anterior-posterior stabilization (as per our current internal hospital standard).
Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
Other Names:
  • 360°-Stabilization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The clinical outcome as assessed by the Oswestry Disability Index (ODI) 104 weeks post-surgery or non-surgical treatment initiation
Time Frame: 2 years after fracture
ODI is a patient-reported outcome measure for spinal disorders. It consists of 10 questions related to back specific disabilities such as pain, personal care, walking and sitting ability, lifting capacity and social life.
2 years after fracture

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiological outcome: Mono- (A3-fractures)/Bisegmental (A4-fractures) kyphosis angle
Time Frame: Pre-Treatment to 2 years after the fracture
Bi-/segmental kyphosis (Gardner/Cobb angle) assessed by long-standing x-rays of the entire spine
Pre-Treatment to 2 years after the fracture
Radiological outcome: Spinal fusion and fracture consolidation
Time Frame: 26 weeks after fracture
Spinal fusion in the surgical group and fracture consolidation in the non-surgical group assessed by CT-scan
26 weeks after fracture
Radiological outcome: Segment mobility
Time Frame: 52 weeks after fracture
Segment mobility assessed by functional lateral views at 52 weeks and compared between treatment groups
52 weeks after fracture
Radiological outcome: Degeneration of the intervertebral disc over time
Time Frame: Pre-Treatment, 52 weeks after the fracture
Degeneration of the intervertebral disc (Pfirrmann grade)
Pre-Treatment, 52 weeks after the fracture
Radiological outcome: Progression of spinal canal stenosis
Time Frame: From the time of fracture, 26 weeks and 52 weeks
Assessed on CT-scan and MRI
From the time of fracture, 26 weeks and 52 weeks
Non-surgical treatment failure rate
Time Frame: From the time of fracture to 2 years after the fracture
Proportion/frequency of patients in the non-surgery group that received surgery later, if there is a clinical indication (spinal instability measured by a kyphosis > 30 degrees on x-ray, intolerable pain, delayed onset of neurological symptoms) or if the patient is not satisfied after treatment
From the time of fracture to 2 years after the fracture
Complication rate and severity and additional surgeries
Time Frame: 6, 12, 26, 52, and 104 weeks
Rate and severity according to the Spine Adverse Events Severity System (SAVES) and surgical complications between treatment groups
6, 12, 26, 52, and 104 weeks
Changes in patient-related outcome measurements: AOSpine Patient Reported Outcome Spine Trauma (PROST)
Time Frame: From the time of fracture to 2 years after the fracture
Changes between groups and from baseline to follow-up 104 weeks and compared between treatment groups
From the time of fracture to 2 years after the fracture
Changes in patient-related outcome measurements: EQ5D-3L
Time Frame: Pre-Treatment to 2 years after the fracture
Changes between groups and from baseline to follow-up 104 weeks and compared between treatment groups
Pre-Treatment to 2 years after the fracture
Changes in patient-related outcome measurements: Pain visual analogue scale (VAS)
Time Frame: Pre-Treatment to 2 years after the fracture
Changes between groups and from baseline to follow-up 104 weeks and compared between treatment groups
Pre-Treatment to 2 years after the fracture
Indirect costs
Time Frame: 6, 12, 26, 52, and 104 weeks
Assessed by indirect cost questionnaire and compared between treatment groups
6, 12, 26, 52, and 104 weeks
Treatment data: Length of hospitalization (days)
Time Frame: Pre-Treatment to discharge from hospital
Inhospital data records, comparison between treatment groups
Pre-Treatment to discharge from hospital
Treatment data: blood loss during surgery (ml)
Time Frame: during surgery
Inhospital data records
during surgery
Treatment data: duration of surgery (hh: mm)
Time Frame: during surgery
Inhospital data records
during surgery
Time to return to work/sports
Time Frame: 6, 12, 26, 52, and 104 weeks
Documented at each clinical follow-up as internal clinic standard of care, comparison between treatment groups
6, 12, 26, 52, and 104 weeks
Radiological outcome: Sagittal and coronal alignment
Time Frame: 6, 12, 26, 52, and 104 weeks
Assessed by long-standing x-rays of the entire spine, comparison between treatment groups
6, 12, 26, 52, and 104 weeks
Opioid use
Time Frame: Pre-Treatment, 6, 12, 26, 52, and 104 weeks
Use of oral intake of opioids, comparison between treatment groups and changes from baseline to 104 weeks
Pre-Treatment, 6, 12, 26, 52, and 104 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiological outcome: Fracture comminution
Time Frame: Pre-Treatment
Fracture comminution of the vertebral body
Pre-Treatment
Radiological outcome: Classification of traumatic disc injury
Time Frame: Pre-treatment
Sanders Classification
Pre-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christoph E Albers, PD Dr., Inselspital Bern, Department of Orthopaedic Surgery and Traumatology
  • Study Director: Sonja Häckel, Dr., Inselspital Bern, Department of Orthopaedic Surgery and Traumatology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 18, 2023

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2030

Study Registration Dates

First Submitted

February 8, 2023

First Submitted That Met QC Criteria

March 2, 2023

First Posted (Actual)

March 15, 2023

Study Record Updates

Last Update Posted (Actual)

May 7, 2026

Last Update Submitted That Met QC Criteria

May 1, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No process has been defined yet how the sharing of the data should proceed

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SPINAL Fracture

Clinical Trials on Surgical stabilization

Subscribe